

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING APPLICATION

Under Rule 53(a), (b) & (f)

(No Filing Fee or Oath/Declaration)

(Do NOT use for Provisional or PCT Applications)Use for Design or Utility ApplicationsPATENT
APPLICATION**RULE 53(f) NO DECLARATION**

Assistant Commissioner of Patents

Atty. Dkt.

PM 254812

M#

Client Ref

and Trademarks

Washington, DC 20231

Date:

July 23, 1999

Sir:

1. This is a Request for filing a new Patent Application (☐ Design ☒ Utility) entitled:

2. (Complete) Title:

METHOD FOR MAINTENANCE AND PROPAGATION OF GERMLINE STEM
CELLS USING MEMBERS OF THE TGF-B FAMILY OF GROWTH FACTORS.without a filing fee or Oath/Declaration but for which is enclosed the following:3. ☒ Abstract 1 page(s).4. 37 Pages of Specification (only spec. and claims); 5. ☐ Specification in non-English language6. 36 Numbered claim(s); and7. ☐ sheet(s) per set: ☐ 1 set informal; 8. ☐ formal of size: ☐ A4 ☐ 11"
Drawings:9. **DOMESTIC/INTERNATIONAL** priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1) 60/094,008	July 24, 1998	(2)	
(3)		(4)	
(5)		(6)	

10. **FOREIGN** priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in

Application No.	Filing Date	Application No.	Filing Date
(1)		(2)	
(3)		(4)	
(5)		(6)	

11. (No.) Certified copy (copies): ☐ attached; ☐ previously filed (date)
in U.S. Application No. / filed on 12. ☐ This is a reissue of Patent No. 13. ☐ See top first page re prior Provisional, National, International application(s) (X box only if info is there and do not complete corresponding item 14 or 15.)14. ☐ **Amend the specification** by inserting before the first line -- This is a ☐ Continuation-in-Part
☐ Divisional ☐ Continuation ☐ Substitute Application (MPEP 201.09) of:14(a) ☐ National Appln. No. / filed .-- (M#)14(b) ☐ International Appln. No. PCT/ filed .--15. ☐ **Amend the specification** by inserting before the first line: --This application
claims the benefit of U.S. Provisional Application No. 60/ , filed .--16. Extension to date: ☐ concurrently filed ☐ not needed ☐ previously filed

17. ☐ Prior application is assigned to

by Assignment recorded _____ Reel _____ Frame _____

18. ☐ Attached:

19. This application is made by the following named inventor(s)

(Double check instructions for accuracy.):

(1) Inventor	Allan	C.	Spradling
	First	Middle Initial	Family Name
Residence	Baltimore	Maryland	United States
	City	State/Foreign Country	Country of Citizenship
Post Office Address	1810 Circle Road, Baltimore, Maryland		
(include Zip Code)	21204		

(2) Inventor	Ting		Xie
	First	Middle Initial	Family Name
Residence	Baltimore	Maryland	China
	City	State/Foreign Country	Country of Citizenship
Post Office Address	500 W. University Parkway, Baltimore, Maryland		
(include Zip Code)	21210		

(3) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(4) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

(5) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

20. NOTE: FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information regarding additional inventors.

Pillsbury Madison & Sutro LLP
Intellectual Property Group

1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918
Tel: (202) 861-3000
Atty/Sec: PNK/GRT/maf

By: Atty: Paul N. Kokulis

Reg. No. 16773

Sig: 

Fax: (202) 822-0944
Tel: (202) 861-3503

NOTE: File in duplicate with 2 post card receipts (PAT-103) & attachments

APPLICATION UNDER UNITED STATES PATENT LAWS

Invention: METHOD FOR MAINTENANCE AND PROPAGATION OF GERMLINE STEM CELLS
USING MEMBERS OF THE TGF- β FAMILY OF GROWTH FACTORS

Inventor (s): Allan C. SPRADLING and Ting XIE

Pillsbury Madison & Sutro LLP
Intellectual Property Group
1100 New York Avenue, N.W.
Ninth Floor, East Tower
Washington, D.C. 20005-3918
Attorneys
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☒ Regular Utility Application
- ☐ Continuing Application
- ☐ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification

Sub. Spec Filed _____
in App. No. ____ / _____

SPECIFICATION

METHOD FOR MAINTENANCE AND PROPAGATION OF GERMLINE STEM CELLS USING MEMBERS OF THE TGF- β FAMILY OF GROWTH FACTORS

RELATED APPLICATIONS

5 This application claims priority from provisional U.S. Appln. No. 60/094,008, filed July 24, 1998.

BACKGROUND OF THE INVENTION

1. Field of the Invention

10 This invention relates to members of the transforming growth factor- β family and their regulation of cell division, cell survival, and the specification of cell fates. Particularly, the invention relates to the bone morphogenetic protein (BMP)-2/4 homolog *decapentaplegic* (*dpp*) and its role in the maintenance of stem cells. For example, a *dpp*-based method for maintenance and controlling the division of germline stem cells, and a *dpp*-
15 based method for defining a niche that controls germline stem cell proliferation are disclosed. Additionally, the invention provides a model of ovarian tumor development. The invention further relates to a *dpp*-based method for propagating stem cells in an undifferentiated state *in vivo* or by culturing *in vitro*.

2. Description of Related Art

20 In many adult tissues that undergo continuous cell turnover, a population of stem cells is responsible for replacing lost cells. Because of their pivotal role in controlling growth and neoplasia, the mechanisms regulating stem cell function are of great interest (reviewed by Potter and Loeffler, 1990; Doe and Spana, 1995; Lin, 1997; Morrison et al., 1997). Two mechanisms have been proposed to maintain stem cell divisions and regulate
25 the differentiation of stem cell daughters: intrinsic factors and extracellular signals. Asymmetrically localized intrinsic factors help specify the fates of neuroblast daughters in *Drosophila* embryos (Doe and Spana, 1995). Extracellular signals from surrounding cells mediated by cell surface-associated ligands and diffusible factors are frequently involved (Potter and Loeffler, 1990; Morrison et al., 1997). The identification of several of these
30 factors has made it possible to culture some types of stem cell *in vitro*.

 The *Drosophila* ovary presents an excellent system for studying two distinct groups of stem cells that remain active during much of adult life (reviewed by Spradling et al., 1997). The adult ovary contains 14-16 ovarioles each with a germarium at the tip, within

which the germline and somatic stem cells are located. Two or three germline stem cells, located at the anterior tip of the germarium, divide asymmetrically to generate all germline cells in the ovariole (Wieschaus and Szabad, 1979; reviewed by Lin, 1997). Stem cell daughters known as cystoblasts undergo four rounds of synchronous division to produce groups of two, four, eight, and eventually 16 interconnected cystocytes, the precursors of ovarian follicles (reviewed by de Cuevas et al., 1997). Two somatic stem cells residing in the middle of the germarium give rise to all the somatic follicle cells (Margolis and Spradling, 1995); their equivalent in the testis are cyst progenitor cells. Three types of mitotically quiescent somatic cells are located in the vicinity of the stem cells: terminal filament and cap cells contact the germline stem cells, while inner sheath cells lie more posteriorly and contact both stem cell types.

Germline stem cell division is known to involve intrinsic mechanisms. This division and subsequent cystocyte divisions are physically unequal due to the segregation of fusomes rich in membrane skeleton proteins such as α -spectrin and an adducin homolog encoded by *hu-li tai shao* (*hts*) (reviewed by de Cuevas et al., 1997). The round fusome (or "spectrosome") characteristic of stem cells changes shape as cyst development proceeds, allowing cysts at different stages to be identified. The *bag of marbles* (*bam*) gene is highly expressed only in the stem cell daughter (McKearin and Spradling, 1990). The loss of Bam protein in cystoblasts prevents their differentiation, causing germline tumors to form (a "tumor" in *Drosophila* is a large clump of proliferating cells, the term does not imply these cells are cancerous). The genes *pumilio* (*pum*) and *nanos* (*nos*), encoding translational regulators, also play critical roles in the formation and maintenance of germline stem cells (Lin and Spradling, 1997; Forbes and Lehmann, 1998).

Less is known about the intercellular signals that control stem cell proliferation. Two important signaling molecules, Hedgehog (Hh) and Wingless (Wg) (reviewed by Perrimon, 1995; Cadigan and Nusse, 1997), are expressed in terminal filament and cap cells (Forbes et al., 1996a and 1996b). Hh signaling is critical for proliferation and differentiation of follicle cells, but it remained to be determined at the time the present invention was made whether somatic stem cells or their daughters are regulated (Forbes et al., 1996a and 1996b). The role of these signals in the germ line was even less clear because ectopic expression of *hh* did not appear to interfere with the function of germline stem cells (Forbes et al., 1996a).

Members of the transforming growth factor- β (TGF- β) family, including TGF- β s, activins, and the bone morphogenetic proteins (BMPs), elicit a broad range of cellular responses including the regulation of cell division, survival, and specification of cell fates (reviewed by Massague et al., 1996; Hogan, 1996a). TGF- β s were previously identified as repressing the proliferation of stem cells as assayed by either *in vitro* cultures or *in vivo* ectopic expression (Potter and Leoffler, 1990; Morrison et al., 1997). Inactivation of BMP-4 and its receptor BMPR in mice resulted in embryonic lethality for homozygous mutants (Winnier et al., 1995; Mishina et al., 1995), but no effect on stem cells was noted.

Similarly *dpp*, encoding a vertebrate BMP-2/4 homolog in *Drosophila*, functions as a local signal as well as a long-distance morphogen to pattern the early embryo and adult appendages by regulating cell proliferation and cell fate determination (Padgett et al., 1987; reviewed by Lawrence and Struhl, 1996). *dpp* is expressed in an anterior subset of follicle cells, and is required for establishing egg shape and polarity during late stages of oogenesis (Twombly et al., 1996). But an effect of *dpp* on maintaining and propagating stem cells, instead of causing their differentiation, has not been previously shown.

Major participants in the *dpp* signaling pathway have been identified: *saxophone* (*sax*) and *thick veins* (*tkv*) encode type I serine/threonine kinase transmembrane receptors, whereas *punt* encodes a type II serine/threonine kinase transmembrane receptor (Brummel et al., 1994; Nellen et al., 1994; Penton et al., 1994; Xie et al., 1994; Ruberte et al., 1995; Letsou et al., 1995). *mothers against dpp* (*mad*), *Medea* (*Med*), and *Daughters against dpp* (*Dad*) encode a family of conserved TGF- β transducers (Sekelsky et al., 1995; Tsuneizumi et al., 1997; Hudson et al., 1998; Wisotzkey et al., 1998; Das et al., 1998; Inoue et al., 1998), collectively known as Smads. Smads are proteins which transduce signals on behalf of TGF- β family members, or inhibit TGF- β signal transduction. A paradigm for TGF- β signal transduction has been developed from several experimental systems (Heldin et al., 1997). In *Drosophila*, Dpp binds both type I and II receptors to allow the constitutively active Punt kinase to phosphorylate and activate type I kinases, which phosphorylate Mad. The phosphorylated Mad brings Med into the nucleus as a transcriptional activator to stimulate *dpp* target gene expression.

Enhancing Dpp or other BMP-like signaling activities can be achieved by reducing the presence of Dad-like proteins, such as human Smad6 and Smad7. Vertebrate Smad6 and Smad7 interact with type I receptors, and are known to inhibit both TGF- β and BMP

signaling in cultured cells and frog embryos. Thus, disinhibition of TGF- β family members by inhibiting certain Smads promotes BMP-like signaling cascades. Additionally, Dpp or other BMP-like signaling activities may be increased by enhancing the function of Dpp or BMP receptors, such as Sax, Tkv, and Punt in *Drosophila*, and BMP receptors BMPR-II, ActR-II, Act-IIB, BMPR-IA, and ActR-I in humans. Other downstream positive regulators of Dpp or BMP signaling include Mad, Med, Dad, and Schnurri proteins in *Drosophila*, and Smad1, Smad4 and Smad5 in humans. See review by Padgett (1999).

Therefore, to address the prior art's failure to identify and characterize factors involved in germline stem cell maintenance and propagation, we now disclose that a member of the TGF- β family of growth factors and its signaling pathway unexpectedly provide this essential function.

SUMMARY OF THE INVENTION

It is an object of the invention to maintain and/or propagate stem cells by stimulating signaling through a bone morphogenetic protein (BMP) signaling pathway. In this manner a population of stem cells can be maintained *in vivo* or *in vitro*, and/or expanded.

Methods for maintaining germline and somatic stem cells of an organism are provided by stimulating a bone morphogenetic protein (BMP) signaling pathway.

The signal transduction pathway associated with a BMP specifically binding to a receptor may involve phosphorylation of serine/threonine residues (e.g., kinases, phosphatases) and a cascade of components of the pathway (i.e., signal transducers such as, for example, transcription factors) which communicate that signal. For example, a signal may be communicated from BMP binding at the cell surface to the nucleus where gene expression of downstream targets are either activated or inhibited. Thus, BMP signaling may be modulated at one or more steps in this pathway, or by affecting upstream regulators or downstream targets of this signaling pathway. Modulation (i.e., stimulation or repression) of BMP signaling may be accomplished directly on the stem cell or indirectly through other cells in a mixed cell population (e.g., feeder layer).

Properties of the stem cell may be maintained by stimulating BMP signaling. Furthermore, stem cells may be increased in abundance and/or increased in lifetime by such stimulation. Conversely, stem cells or tumor cells in a population may be reduced in total number or concentration, or even eliminated at the limit of detection, by repressing BMP signaling.

Stem cells may also be propagated and isolated according to the invention.

Our invention addresses the problem of restricted access to and limited numbers of stem cells. The ability to maintain and to propagate stem cells facilitates genetic manipulation and the characterization of these rare cells.

5

DESCRIPTION OF SPECIFIC EMBODIMENTS

The present invention provides a method for maintaining and controlling the division of germline stem cells in which *dpp* can provide an essential role. Further, it provides a model of ovarian tumor formation in which overexpression of *dpp* produces ovarian stem cell tumors. Clonal analysis demonstrates that downstream components (i.e., signal transducers) of the *dpp* signaling pathway are required cell-autonomously in the germline stem cells for their division and maintenance. This invention also provides a method for control of a cellular niche by BMP signaling, in which germline stem cells are regulated by, for example, a *dpp* signal that likely derives from surrounding somatic cells.

15 Stem cells are thought to be regulated by positive and negative diffusible factors, but the functions of most of these factors have never been demonstrated *in vivo*. The present invention provides a method in which Dpp directly signals to maintain *Drosophila* germline stem cells and stimulate their division. The experiments of the examples were made possible by a clonal cell marking method that allows the function of stem cells and their progeny to be examined directly over many cell generations. In addition to the *dpp* signal, known components in the *dpp* signal transduction pathway were shown to be required in these adult stem cells. This action appears to be specific to stem cells, since germ cells lacking *dpp* pathway components were still able to form 16-cell cysts. The examples demonstrate that a TGF- β -like molecule functions as a stem cell growth factor.

25 *dpp* signal transduction is required for maintaining stem cells, on which Dpp may act in several distinct ways. Signaling prevents germline stem cells from differentiating into cystoblasts and gametes. The examples show that overexpressed *dpp* prevents stem cell differentiation, while reduction of *dpp* function promotes stem cell differentiation. An attractive candidate target of the *dpp* signal transduction pathway is the Bam protein, which is normally synthesized at much higher levels in cystoblasts than in stem cells (McKearin and Ohlstein, 1995). The forced expression of Bam in germline stem cells causes them to differentiate in a manner very similar to that caused by reductions in *dpp* signaling (Ohlstein and McKearin, 1997). Thus, *dpp* signaling may negatively regulate

30

Bam protein levels in germline stem cells. Two other genes, *pum* and *nos*, are required to form and maintain germline stem cells (Lin and Spradling, 1997; Forbes and Lehmann, 1998). In the embryo, both proteins work together to repress the translation of target genes such as *hunchback* (*hb*) (Baker et al., 1992; Murata and Wharton, 1995). In the ovary, *dpp* signaling may downregulate Bam through effects on the Nos/Pum pathway or by an independent mechanism. However, genes throughout the *dpp* pathway are required, including two nuclear transcription factors, suggesting that the action of the pathway is on transcription of target genes. Also see reviews by Attisano and Wrana (1998), Kawabata et al. (1998), and Padgett et al. (1998).

dpp may also function to maintain a specialized association between the stem cells and basal terminal filament cells. Such an association has been postulated to hold the stem cells at the anterior of the germarium, while daughter germline cells all move posteriorly and eventually leave the germarium. The results presented herein indicate that the stem cell loss is due to differentiation. Possibly, *dpp* signaling via its receptor regulates the expression of adhesion molecules that reside on the cell surface or of cytoplasmic proteins that indirectly promote stem cell adhesion.

dpp signaling also may act to stimulate stem cell division. *dpp* signaling stimulates cell proliferation at several points during *Drosophila* development. In the wing imaginal disc, it is essential for cell proliferation and/or survival (Burke and Baster, 1996), whereas it promotes the G2-M transition in the morphogenetic furrow of the developing eye disc (Penton et al., 1997). Consistent with such a requirement, *mad* mutants have greatly reduced imaginal discs, shortened gastric caeca, and small brains (Sekelsky et al., 1995). The requirement for *dpp* signaling disclosed herein suggests that adult stem cells use strategies similar to those of embryonic and larval somatic cells to regulate proliferation. For example, *dpp* stimulates the rate of cell division for stem cells.

During aging, the number and activity of stem cells are thought to be reduced. The examples indicate that the level of *dpp* signaling controls the life span and division rate of germline stem cells. Reduced *dpp* signaling caused premature stem cell loss. Perhaps more surprising is the observation that putative increases in signaling, caused by removal of Dad protein activity from stem cells, permitted stem cells to be maintained longer. This finding suggests that *dpp* signaling not only is necessary, but may sometimes be rate limiting for stem cell maintenance. The illustrative examples demonstrate for the first time a method in which stem cell life span has been extended in an intact organism.

These results suggest that it may be possible to extend the life span of stem cells, a process that could be of therapeutic significance. For example, drugs that upregulate BMP signaling to stem cells may enhance fertility in humans and animals, such as male fertility in patients with reduced numbers of germline stem cells (basal cells). Such drugs may ameliorate hematologic conditions caused by reduced stem cell functioning, for example aplastic anemias, agammaglobulinemia, and related conditions. Drugs enhancing BMP signaling may enhance wound healing. Aging-related pathologies caused by loss of stem cells, such as hair loss, loss of muscle mass, reduction of blood cell numbers, and the aging of the skin and other stem cell-dependent tissues could be treated by increasing BMP signal transduction. Compounds enhancing BMP signaling may increase the average lifespan of an organism.

One method for the enhancement of *dpp* signal transduction may be facilitated by removal of the *dpp* inhibitor Dad or other Dad-like inhibitory protein activity (inhibitory Smad activity) from the germline stem cells. Dad is induced by *dpp* signaling, but then acts to downregulate the very pathway that activated its production. This method could also be practiced with other negative regulators of the *dpp* signaling pathway and, in particular, inhibitory Smads. In contrast, *brinker* (*brk*) is a target gene repressed by *dpp* signaling and, because it is itself a transcriptional repressor, the net effect of repressing expression of the Brk repressor is to upregulate Brk-regulated target genes (Minami et al., 1999; Campbell et al., 1999; Jazwinska et al., 1999). This results in the increased production of Brk-regulated target genes following *dpp* signaling. Hence, BMP signaling can be stimulated or repressed by appropriate manipulation of Smads or target genes which are regulated by BMP signaling (i.e., increasing or decreasing their effects as appropriate to achieve stimulation or repression of BMP signaling). The roles of Dad and Brk, like the rest of the pathway, appear to be conserved in mammals.

Drugs that inhibit BMP signaling to stem cells may be useful chemotherapeutic agents. For example, drugs inhibiting BMP signaling pathways may be useful therapies against teratocarcinoma by causing stem cell differentiation. As another example, drugs which inhibit BMP signaling may be successful treatments against ovarian germline tumors dependent upon BMP signaling for continued growth.

Increased or decreased BMP signaling to stem cells might allow populations of stem cells to expand prior to bone marrow transplant, thereby increasing the chances of successful transplantation and reducing the amount of donor marrow required. Further,

control of BMP signaling pathways may permit stem cells other than those in bone marrow to be removed from a patient, expanded *in vitro*, and subsequently reintroduced in to the patient to repair tissues damaged by injury or disease, such as Parkinson's disease.

Bone marrow from patients with hematologic tumors, such as lymphoma and leukemia, could be tested for BMP sensitivity. Positive test results for BMP sensitivity would allow steps to be taken to avoid potential side effects of anti-BMP treatment *in vivo*. For example, marrow removed from the patient could be cleansed of tumors cells by inhibiting BMP signaling, thereby inducing differentiation of tumor cells and reducing the tumor burden. The cleansed marrow would subsequently be returned to the patient in an autologous bone marrow transplant. Such differentiation therapy could also be used for solid tumors like sarcoma, carcinoma, and neuroglioma to reduce tumor burden. Therapy may be use alone or in association with other treatments such as, for example, chemotherapy, hyperthermia, or radiation which preferentially kills rapidly dividing cells and surgical resection of tumor.

Upregulation of BMP signaling to stem cells may permit the growth of germline stem cells in culture, useful in, for example, generating transgenic animals. Such techniques are especially useful in organisms which have not traditionally been used as genetic models of development and disease.

The ability to expand stem cell niches by overexpression of TGF- β members, such as *dpp* may allow rare human stem cells, or alternatively rare stem cells of any species, to be purified and propagated following transfer into living *Drosophila*, which have been genetically engineered to serve as hosts.

Beside biomedical research and treatment, other uses for the present invention include agriculture and wildlife conservation. Stem cells could be provided in or obtained from humans, primates (e.g., bonobo, chimpanzee, gorilla, macaque, orangutan), companion animals (e.g., dog, cat), and farm/laboratory animals (e.g., cattle, donkey, goat, horse, pig, sheep; amphibians such as frog, salamander, toad; birds such as chicken, duck, turkey, fishes such as carp, catfish, medaka, salmon, tilapia, tuna, zebrafish; lagomorphs such as hares, rabbits; rodents such as mice, rats).

Stem cells could be maintained and/or maintained in an appropriate niche or in culture, and used as a source of nuclei for cloning progeny organisms via nuclear transfer or a source of cells for propagation of mosaic organisms via embryo aggregation. Thus,

Dpp or related BMPs provide a means for growing stem cells *in vitro* or *in vivo* for cloning animals.

BMP signaling is unlikely to be confined to one type of BMP and only type of BMP receptor because of the ability of evolutionarily diverged components of the BMP signal transduction pathway or different types of BMPs, BMP receptors, and SMADs to be functional equivalents of each other. For example, there appears to be crosstalk between Dpp/Tkv signaling and Gbb/Sax signaling (Haerry et al., 1998) and one signal transducer acts in different signaling pathways (Lagna et al., 1996). For example, a mixture of BMPs could be added to defined culture medium or be present in conditioned culture medium such that Dpp and Gbb would synergize in initiating BMP signaling through more than one different types of BMP receptor. As another example, one type of signal transducer could stimulate signaling through more than one different types of BMP receptor.

To stimulate BMP signaling, a positive signal transducer could be increased in expression (e.g., more transcripts and/or translated products) or mutated to a gain-of-function phenotype to increase activity of that signal transducer, while a negative signal transducer could be decreased in expression (e.g., fewer transcripts and/or translated products) or mutated to a loss-of-function phenotype to decrease activity of that signal transducer. Alternatively, a downstream target gene of BMP signaling could be directly activated or inhibited without BMP binding to its receptor by genetic engineering using a transactivator like GAL4 binding its UAS or ecdysone receptor binding upstream of the target gene. Similar techniques in mice involve induction with tetracycline or FK506.

Another method would be to increase endogenous BMP activity in the cells or to increase exogenous BMP activity outside the cells, especially if ligand is the limiting component in BMP signaling. For example, BMP expression may be increased in a stem cell and stimulate BMP signaling through an autocrine mechanism. Alternatively, BMP expression may be increased in a non-stem cell or a feeder cell, and then BMP activity could be secreted and taken up by the stem cell or brought into contact with the surface of the stem cell. BMP could also be added to the extracellular space or culture medium. BMP activity may be increased to stimulate BMP signaling by at least about 10%, 50%, 100%, or 200% as compared to the amount normally present in the animal or the culture.

Properties of the stem cell which may be maintained include the following: pluripotency, totipotency, committing to one or more differentiating cell lineages, giving rise to multiple different types of progenitors and/or differentiated cells, contributing to the germ-

line, and combinations thereof. Thus, the growth and/or survival of stem cells may be maintained without commitment to a program of differentiation, while retaining the capacity to differentiate normally under appropriate conditions following reduction or elimination of BMP signaling. More simply, stem cells in a population may be expanded
5 in total number or concentration relative to non-stem cells (i.e., an increase in abundance), extended in the time between a stem cell's birth and its death or apoptosis (i.e., an increase in lifetime), or combinations thereof. Conversely, stem cells or tumor cells in a population may be reduced in total number or concentration, or even eliminated at the limit of detection, by repressing BMP signaling.

10 Stem cells made according to the present invention may be totipotent or pluripotent, male or female, germline or somatic, dividing or quiescent, vertebrate or invertebrate, present *in situ* or isolated, partially or substantially purified of differentiate cells, and combinations thereof. Proliferating stem cells are diploid, entering meiosis and the later stages of gametogenesis is part of the program of differentiation for male or female germ-
15 line stem cells that is prevented by the present invention. Stem cells may be present in or obtained from testis, ovary, especially apical tips of *Drosophila* testes and/or ovarioles, or other adult or embryonic tissues. By differentiating, stem cells may differentiate into cells of the hematopoietic, immune, or nervous systems or the like. Preferably, stem cells maintained and/or propagated by the present invention retain the potential to later differentiate
20 and thereby contribute to oogenesis or spermatogenesis, all three germ layers (i.e., endoderm, mesoderm, ectoderm), multiple differentiated cell lineages, and combinations thereof.

Somatic cells include terminal filament cells, cap cells, and inner sheath cells from the ovary and hub cells from the testis. Preferably, the present invention reduces the proportion of somatic cells in a population relative to germline cells during maintenance and/
25 or propagation. A niche defined by surrounding somatic cells or a feeder layer comprised of somatic cells may provide cell contact and other extracellular signals to maintain and/or propagate germline cells. A feeder layer may be provided that provides certain essential extracellular signals by, for example, genetically manipulating cultured cells to express
30 and secrete a BMP which then binds to its receptor on the stem cells.

Cell populations may be derived from the germline or somatic (or mixed), male or female, dividing or quiescent, vertebrate or invertebrate, present *in situ* or isolated, partially or substantially purified, and combinations thereof. Preferably, cell populations include

cells expressing one or more BMPs; more preferably, BMP is secreted by non-stem cells and binds to receptors of stem cells to stimulate BMP signaling. Thus, stem cells of the present invention contain receptors for BMP, especially Dpp or a homolog, or are at least responsive to BMP signaling.

5 Besides mammals, amphibians, birds, and fishes, other organisms may be used in the present invention such as invertebrates like worms (e.g., Helminthes, Nematodes) and insects (e.g., Anopheles, Drosophila). In particular, comparison of components of the BMP signaling pathway, upstream regulators, and downstream targets show them to be highly conserved (Bitgood and McMahon, 1995; Padgett et al., 1998). Thus, the present
10 invention should not be limited in its usefulness to *Drosophila melanogaster*. Other species which show conservation of *dpp* (Newfeld et al., 1997) and are likely to be useful are *D. simulans*, *D. pseudoobscura*, and *D. virilis*. For metazoan species in which there has been a diligent search, a *dpp*-like gene has been identified.

 Mammalian homologs of *dpp*, *glass bottom boat (gbb)*, and *screw (scw)* have been
15 identified as BMP-2/4, BMP-5/8, and BMP-6, respectively (Hoffmann, 1997; Raftery and Sutherland, 1999; Wharton et al., 1999). A mammalian serine/threonine kinase receptor has been identified that specifically binds BMP-2 and BMP-4 (Yamaji et al., 1994). Other related members of the TGF- β family, their receptors, or other components of their signaling pathways, might also be used in the present invention. See also U.S. Pat. Nos.
20 5,011,691, 5,013,649, 5,166,058, 5,168,050, 5,216,126, 5,324,819, 5,354,557, 5,635,372, 5,639,638, 5,650,276, and 5,854,207.

 Furthermore, mutational analysis and determination of structure-function relationships have identified conserved residues and essential residues for Dpp signaling (Wharton et al., 1996). Bacterially expressed Dpp can be refolded, then biochemically and biophysically characterized (Groppe et al., 1998). Homologs of a member of the BMP family,
25 their receptors, and other components of the signaling pathway can be identified by a high level of structural conservation when amino acid sequences are compared, and/or functional conservation when homologs rescue mutant phenotypes or otherwise replace BMP activity.

30 Cell types have been identified by markers and are well characterized by genetic mutants and developmental studies. Stem cells may be provided *in situ* as part of an intact organism or they may be cultured *in vitro*. Germline stem cells and surrounding cells may be from an adult (e.g., ovary, testis) or an embryo. For *in vitro* culturing, cells may be

obtained directly from an organism (i.e., primary culture) but it would be convenient to passage them through several cultures (e.g., at least five, ten, or twenty times) to expand their number (e.g., at least two, ten, or 100 times more than the original number).

Stem cells may be isolated from a donor organism with or without increasing cell number by stimulating BMP signaling; manipulated during transient *in vitro* culturing under conditions for maintenance and/or propagation by treating with one or more chemicals, introducing genetic material, fusing with another cell, mutating one or more genes, selecting a desired genotype or phenotype, or combinations thereof; and transplanting stem cells back into a host which is identical to the donor (i.e., autologous transplantation), similar to the donor but different (i.e., allogeneic transplantation), or is totally different from the donor (i.e., xenogeneic transplantation). *In vitro* culture conditions, genetic engineering of *Drosophila* by transfection and site-specific recombination, and cell or nuclear transplantation are known in the art.

For *Drosophila*, there are only about 10 germline stem cells per testis and about 32-48 germline stem cells per ovary (i.e., there are about 16 ovarioles per ovary and about two or three germline stem cells per ovary). The present invention provides greatly increased numbers of stem cells to be produced *in vivo* in an adult or embryo, and then cultured *in vitro*. *In vitro* culture of cells may be carried out by initially generating flies with a large number of germline stem cells in each ovariole. Then ovaries may be removed surgically into sterile culture medium and the germ cells released (they do not adhere and, thus, do not need to be disaggregated). Alternatively, disaggregated embryos may also be used as a source of germline stem cells. Although the number of germ cells per embryo is similar to the number per ovary and testis, it is possible to start with 100,000 embryos but only a few hundred gonads can be easily obtained. Schneider (1972) shows derivation of a cell line from *Drosophila*.

Drosophila cells may be plated into small wells containing feeder layers of cells expressing Dpp (e.g., Panganiban et al., 1990) or Hh (e.g., Lee et al., 1994), or culture media prepared by conditioning the media with cells secreting soluble factors or simply adding a recombinantly produced soluble factor (e.g., Dpp produced according to Groppe et al., 1998). *In vitro* culture media for growing *Drosophila* cells are commercially available such as, for example, Schneider's *Drosophila* medium. *Drosophila* cells can also be adapted and grown in mammalian tissue culture media (Spradling et al., 1975; Lengyel et al., 1975). *Drosophila* cells can be transfected like mammalian cells (Burke et al., 1984).

Constructs and strategies for homologous recombination in somatic, embryonic stem (ES), and embryonic (EG) cells could be adapted for use with *in vitro* cultured *Drosophila* cells (Capeocchi, 1989; Koller and Smithies, 1992). Cultured cells or their nuclei may then be transferred into *Drosophila* (Okada et al., 1974; Van Deusen, 1977).

5 Previous attempts at culturing germline stem cells utilized the 40 germline cells present in each embryo at a certain stage of development. But no *dpp* was provided, and these cells differentiated in culture (Allis et al., 1979). Inducing BMP expression in cells of such cultures or adding exogenous BMP to them would be a simple way of maintaining and/or propagating germline stem cells *in vitro*.

10 A BMP may also be used in replacement of, or combination with, known stem growth factors such as, for example, fibroblast growth factor (FGF), leukemia inhibitory factor (LIF), and steel factor (SF). Thus, BMP activity as observed herein might also be demonstrated using the techniques taught in U.S. Pat. Nos. 5,453,357 and 5,690,926.

15 *Ex vivo* culturing of stem cells with stimulation of BMP signaling only performed outside the body is preferred to avoid systemic effects of BMP signaling on the organism.

20 Vascular or organ engineering may be accomplished with stem cells that differentiate into endothelium or parenchyma, respectively, with or without an implantable support (e.g., stent, hollow fiber or particle) on which stem cells have been coated or impregnated. If not autologously transplanted and in an organism with an immune system recognizing histoincompatibility, transplantation of allogeneic or xenogeneic tissue may require immunosuppression of the host (e.g., cyclosporine A or FK506 treatment). Differentiation of stem cells into tissue with the activity and/or structure of adrenal gland, bone marrow, brain, liver, ovary or testis, pancreas, peripheral neurons or glia, red or white blood cells, skeletal or smooth muscle, skin, thyroid gland, or combinations thereof is preferred.

25 One or more genes of the stem cell may be activated or inhibited by chemical or environmental induction, antisense, ribozyme, chimeric repair vector, RNAi, or random/sequence-specific insertion. Ectopic expression of a gene may be controlled in a particular spatial or temporal manner, mimic pathologic or disease states, or create phenocopies of mutations in the endogenous gene. Homologous recombination is preferred to achieve gene knockout or replacement (see, e.g., U.S. Pat. Nos. 5,569,824, 5,602,307, 5,614,396, 30 5,683,906, and 5,830,682). For example, stem cells may be transfected with a polynucleotide, the polynucleotide or a portion thereof integrates into the genome of transfected stem cells at a random site or in a sequence-specific manner, homologous recombinants at a

genetic loci of interest are selected, and the selected stem cells are transplanted into a host organism. Physical introduction of polynucleotides (e.g., biolistics, electroporation, microinjection) is preferred. Alternatively, insertion of P elements may be genetically engineered *in vivo* or *in vitro* in a stem cell maintained and/or propagated according to the present invention to disrupt genes (cf. Zhang and Spradling, 1994; Spradling et al., 1995).

TGF- β signaling has been shown to limit the growth of germline cysts during *Drosophila* spermatogenesis (Matunis et al., 1997). When *punt* or *shn* function is removed in clones of somatic cells that surround germ cells, cysts continue dividing after four rounds of mitosis (Matunis et al., 1997). However, these investigators did not address whether this pathway functions in male germline stem cells. In the embryo and imaginal discs, *punt* and *shn* can function downstream of *dpp* (Ruberte et al., 1995; Letsou et al., 1995; Arora et al., 1995; Grieder et al., 1995), but it was not known whether *dpp* or another TGF- β family member is utilized to send the signal. Clonal analysis of mutants in *dpp* downstream components in male germline stem cells, like those reported here in the ovary, could show whether Dpp and/or other TGF- β -like molecules are required for their division and maintenance in the testis.

In mouse, the BMP family members BMP-2 and -4 are most closely related to *dpp*, with greater than 75% identity, and can function to rescue *dpp* mutants in embryos (Padgett et al., 1993). Recently, both genes have been inactivated by homologous recombination, but the homozygous embryos die too early to assess possible functions in the gonads (Winnier et al., 1995; Zhang and Bradley, 1996; reviewed by Hogan, 1996b). Consistent with our findings, Lawson et al. (1999) report that BMP-4 affects the number of primordial germ cells; moreover, BMP4 was needed in somatic tissue, and presumably stimulated BMP signal transduction in germline cells, although this was not shown directly. The roles during spermatogenesis of two other BMP family members, BMP-8A and BMP-8B, have been tested (Zhao et al., 1996; 1998). BMP-8B is required for the resumption of male germline cell proliferation in early puberty, and for germline cell survival in the adult, whereas BMP-8A plays a role in the maintenance of adult spermatogenesis.

The "niche" hypothesis postulates that stem cells reside in optimal microenvironments or "niches" (Schofield, 1978). When a stem cell divides, only one daughter can remain in the niche while the other becomes committed to differentiate. A stem cell within the niche would have a high probability of self-renewal, but a low probability of entry into the differentiation pathway. This model is consistent with the observations that

stem cells require the addition of growth factors for proliferation and differentiation in many *in vitro* culture systems (Potter and Loeffler, 1990; Morrison et al., 1997). The molecular nature of the microenvironment within a niche has yet to be defined in any system, although the *Drosophila* germarium appears to contain such a niche. Anteriorly, the stem cells abut terminal filament and cap cells, which both express *hh*, while only the latter express *armadillo* (*arm*) and *wg* (Forbes et al., 1996a; 1996b). Stem cell daughters lie more to the posterior, and probably directly contact inner germarial sheath cells, which express *patched* (*ptc*) and *hh* (Forbes et al., 1996b). This asymmetry in structure and signals may allow germline stem cells to receive different levels of signals from their daughters. Consistent with the existence of a niche, two wildtype stem cells in germaria that recently lost a marked mutant stem cell were occasionally observed, suggesting that a vacated niche could be reoccupied.

The existence of the germline stem cell niche is also consistent with stem cell proliferation when local *dpp* is overexpressed. Under these conditions, the size of the niche may be substantially enlarged. Conversely, reduction of *dpp* function may weaken the ability of the niche to maintain germline stem cells, leading to accelerated losses. These results suggest that *dpp* is an essential niche signal. However, *dpp* likely interacts with other signals from surrounding somatic cells to make a functional niche for germline stem cells. Nonetheless, the identification of *dpp* as a key niche signal should greatly facilitate efforts to culture *Drosophila* germline stem cells *in vitro*.

Technical limitations have previously prevented identification of the source of the *dpp* signal that is received by germline stem cells. Ideally, analysis of clones of a null *dpp* allele would reveal which cells produce the signal. However, the somatic cells adjacent to the stem cells cease division early in ovary development and make induction of specific small clones difficult. The pattern of *dpp* expression in the germarium should also provide some insight into the origins of the signal. However, the only available *dpp-lacZ* fusion line and whole mount *in situ* experiments failed to detect expression in the germarium, although follicle cell expression in late stage egg chambers was observed. We now show that somatic cells in the niche express *dpp*. In many systems, low levels of *dpp* expression are known to be sufficient for biological effects so it may be sufficient to provide only low levels of BMP in the present invention.

In the *Drosophila* leg, antenna and genital discs, *dpp* and *wg* are induced in the anterior compartment by *hh*, and the mutual repression of *dpp* and *wg* restricts them to

their appropriate domains (Brook and Cohen, 1996; Jiang and Struhl, 1996; Chen and Baker, 1996). In vertebrate limb development, *sonic hedgehog* (*shh*) can induce the expression of BMP-2 (Johnson and Tabin, 1995). The somatic terminal filament, cap, and inner sheath cells express *hh* and lie adjacent to the germline stem cells (Forbes et al., 1996a, 1996b). *wg* and *dpp* expression may be induced by *hh*, and signal to germline stem cells for their proliferation and maintenance. The data indicate that these and possibly additional signals from the anterior somatic cells define a niche for germline stem cells at the tip of germarium. Thus, agents which modify hedgehog signaling may be used to alter local BMP signaling, thereby regulating stem cell maintenance and/or propagation.

EXAMPLES

Example 1: Ectopic Dpp Expression Induces Germ Cell Tumors.

To assess whether Dpp can regulate germline stem cells in the *Drosophila* adult ovary, Dpp was ectopically expressed in the germarium using *hsp70-GAL4* (*hs-GAL4*) and *UAS-dpp* (Brand and Perrimon, 1993). To distinguish different cell types in the germarium, we used anti-Hts and anti-Vase antibodies to visualize somatic and germline cells, respectively. The anti-Hts antibody also recognizes spectrosomes and fusomes in the germline cells of the germarium (see de Cuevas et al., 1997).

Only germline stem cells and cystoblasts have a big round spectrosome, while cysts have a characteristic branched fusome. In the wildtype germarium, two germline stem cells are more anteriorly located than cystoblasts. Developing cysts in germarial regions 1 and 2a (i.e., the anterior half), which are more posterior than germline stem cells and cystoblasts, are connected by fusomes. In the germarial regions 2b and 3, both lens-shaped and round cysts span across the germarium, and become surrounded by somatic follicle cells. Fusome structures begin degeneration in these older cysts.

The germaria from *hs-GAL4* females subjected to heat shock, and those from females carrying *hs-GAL4* and *UAS-dpp* in the absence of a heat shock, were indistinguishable from wildtype. In these heat shock-treated germaria, large single germline cells filling the corresponding wildtype germarial regions 1 and 2a contained spectrosomes but showed no evidence of cyst formation. In the corresponding wildtype regions 2b and 3, both lens-shaped and round cysts were observed that probably derived from differentiated cystoblasts or cysts that had formed before the initial heat shock.

Consistent with this interpretation, after 4-5 days of heat shock, all germline cells in the corresponding regions 1 and 2 were single cells containing spectrosomes and developing cysts containing branched fusomes were rarely detected. Only somatic follicle cells were detected, there were no germline cells. This phenotype is very similar to that of *bam* and *benign gonial cell neoplasm (bgcn)* mutants (McKearin and Spradling, 1990; Gateff and Mechler, 1989).

Here, instead of the wildtype number of two or three germline stem cells per ovariole, dozens were present in a single ovariole. Moreover, the number present was 2-3 times greater after 4-5 days than after 3 days. Because there are 16 ovarioles per ovary and two ovaries per female fly, all of the above numbers should be multiplied by 32 to calculate the number of female germline stem cells per fly. The germline stem cells proliferate following induction of *dpp* to form a large mass of normal appearing, normal functioning germline stem cells. The proliferating cells were shown to be germline stem cells based on (1) general size and appearance, (2) fusome morphology, (3) expression of the germ cell-specific gene *vasa*, (4) absence of expression of cytoplasmic Bam (i.e., a sensitive indicator that germline stem cells have differentiated into cystoblasts), and (5) ability to differentiate along the normal pathway for germline cells following removal of *dpp*.

Example 2: Dpp-Induced Tumor Cells Resemble Germline Stem Cells.

Cystoblasts and early mitotic cysts can be distinguished from stem cells because the former express cytoplasmic Bam protein from the cystoblast stage to the end of the 8-cell stage cyst stage. Immunofluorescent staining of the wildtype germarium with anti-BamC and anti- α -spectrin antibodies document that cystoblasts and developing cysts, but not germline stem cells, express cytoplasmic Bam protein. Immunofluorescent staining of *dpp*-induced germaria with anti-BamC and anti- α -spectrin revealed that amplified single germline cells failed to express the cytoplasmic Bam protein. In *dpp*-induced germaria, a few, rare BamC-positive cells were observed that appeared to be growing cysts. These data show that the large number of single germline cells induced by *dpp* overexpression resemble stem cells rather than differentiated cystoblasts.

To determine that this absence of BamC-staining was not due to growth arrest of the accumulated single germline cells, *dpp*-induced germaria were stained with anti-BrdU and anti- α -spectrin antibodies following incorporation of the nucleotide analog BrdU for one hour. Mitotically active germline cells in their S-phase of the cell cycle can incorpo-

rate BrdU. In the *dpp*-induced germaria, some single germline cells incorporated BrdU, indicating that these single germline cells have not undergone growth arrest.

These results show that the tumor cells induced by *dpp* overexpression continue to divide, and resemble stem cells in their fusome morphology and absence of Bam protein.

5 They represent an increased number of germline stem cells.

To determine if these *dpp*-induced stem cells retain the capacity to differentiate, their behavior was examined. *hs-GAL4/UAS-dpp* *Drosophila* were induced by four days of heat shock-treatment, and then returned to room temperature for 2 or 4 days prior to staining with anti-Hts and anti-Vase antibodies. Germline cysts were observed starting to
10 form two days after the temperature downshift and always formed initially in the most posterior region of the tumor. Many 16-cell cysts were seen 4 days after the shift back to room temperature. Based on their location and number, these cysts must derive from *dpp*-induced germline stem cells, rather than from stem cell divisions that occur after the downshift. But not all the *dpp*-induced germline stem cells were able to form complete cysts,
15 because some ovarioles contained cysts with one, two, four, or eight cells in region 3.

Example 3: Overexpressed *dpp* Acts Directly on Germline Stem Cells.

Two different models could explain the Dpp effect on germline stem cells: direct signaling to the germline stem cells and relay signaling. The relay signaling model predicts that ectopic Dpp turns on a secondary signal in the somatic cells surrounding germ-
20 line stem cells.

To directly test the relay model, the *hs-GAL4/UAS* system was used to activate Dpp type I receptors. The *hs-GAL4/UAS* system can express a target gene at high levels in somatic cells of the adult ovary, but not in germline cells (Manseau et al., 1997). Both activated *tkv* (*tkv**) (Nellen et al., 1996) and activated *sax* (*sax**) (Des et al., 1998) have
25 been shown to mimic *dpp* signaling pathway activation in many developmental processes.

Overexpression of activated Dpp type I receptors in the somatic cells of the germlarium does not mimic the effect of ectopic *dpp* expression. Flies of the following genotypes were subjected to heat shock-treatment for three days, and germaria were subsequently labeled with anti-Vase and anti-Hts antibodies: *hsGAL4/UAS-sax**,
30 *hsGAL4/UAS-tkv**, and *UAS-sax*/+;hsGAL4/UAS-tkv**. Two independent lines containing the *UAS-tkv** and *UAS-sax** insertions at different chromosomal sites were tested. When activated *sax** or *tkv**, or both, were overexpressed in the somatic cells of the germlarium using *hs-GAL4*, the same driver for *dpp* overexpression, no germline stem

cell proliferation was observed. But egg chamber budding was frequently affected in region 3 cysts in the *hsGAL4/UAS-*tkv***, and *UAS-sax*/+;hsGAL4/UAS-*tkv*** lines, suggesting that somatic follicle cell function was defective at a later stage.

These results suggest that relay signaling, regardless of its mechanism, is by itself not sufficient to inhibit germline stem cell differentiation. Since overexpressed Dpp does not appear to act by a relay signal, it likely acts directly on germline cells via functional Dpp receptors to inhibit cystoblast differentiation.

Example 4: Dpp and Sax are Required for Germline Stem Cell Division and Maintenance.

To directly test the role of *dpp*, we examined mutations that reduce its function and that of the Dpp receptor *sax*. Dpp signaling is essential at many points during *Drosophila* development. Several temperature-sensitive allelic combinations of *dpp* mutants, including *dpp^{e90}/dpp^{hr56}* and *dpp^{hr4}/dpp^{hr56}*, can develop into adults at 18°C (Wharton et al., 1996). These heteroallelic combinations allowed us to examine the mutant phenotypes of *dpp* in the germarium after the shift to 28°C. Forty to 50% of germaria from these genotypes examined one week after the temperature shift were significantly smaller than heterozygotes, and more severe reductions were seen in older females maintained at the higher temperature. To determine if stem cells were being lost, ovaries from the mutant females were stained with anti-Hts and anti-Vase antibodies and the number of stem cells in each ovariole were directly counted (Table 1). There was a dramatic reduction in germline stem cell number in both tested genotypes over a two week period. The stronger of the two, *dpp^{hr4}/dpp^{hr56}*, almost completely eliminated stem cells within two weeks. This combination produces many fewer adult flies and is known to disrupt embryonic development more severely than *dpp^{e90}/dpp^{hr56}* (Wharton et al., 1996).

If the mutations act specifically on germline stem cells, cystoblasts and cysts should continue to divide and develop. To examine this, the morphology of fusomes in the mutant ovarioles were analyzed. Ovarioles from the Dpp receptor mutant *sax^P*, which has a weaker effect on stem cell number were also studied. The timing of stem cell loss is expected to vary among individual germaria, because stem cell loss is a random process (Margolis and Spradling, 1995).

Control germaria from one week-old *sax^P/+* and *dpp^{e90}/CyOP23* females were double labeled with anti-Vase and anti-Hts antibodies. In both cases, germaria from one week-old females heterozygous for the *dpp* or *sax* alleles generally contained two stem

cells at the anterior. The mutant germania were also double labeled with anti-Vase and anti-Hts antibodies.

Mutant *sax^P/sax^P* germaria from one week-old females were smaller than wildtype. In one case, two stem cells were observed but the number of cysts was reduced. In another case, one stem cell remained and regions 1 and 2a were much reduced as indicated by the start of region 2b. This indicates that stem cells were being lost and their division slowed.

Many germaria in two week-old mutant *sax^P/sax^P* females had lost both stem cells and no mitotic cysts were present, although cysts and egg chambers at later developmental stages remained (e.g., the most anterior cyst corresponding to region 2b).

Mutant *dpp^{e90}/dpp^{hr56}* females showed a more rapid loss of stem cells at 28°C. Such germaria frequently contained one or zero stem cells after one week. In one case, only one stem cell and no mitotic cysts were found; the most anterior cyst contained 16 cells. In another case, no stem cells were present; an 8-cell cyst and a 16-cell cyst lay at the anterior. After two weeks, most ovarioles lacked stem cells entirely, but some still contained 16-cell cysts or older follicles.

Because normal cystocyte development continued throughout the germarium, the effects of these mutations appear to be limited largely to stem cell division and maintenance. Some abnormalities in a later process, egg chamber budding, were observed. Stem cell loss might be caused by either cell death or differentiation. Apoptotic cells were not observed in the most anterior region of these germaria where germline stem cells are located based on DAPI staining.

These results indicate that a reduction in the level of *dpp* signaling promotes the differentiation of germline stem cells into cysts, and thus causes stem cell loss. Consistent with previous studies (Twombly et al., 1996), we observed some partially ventralized eggs with anterior defects in these *dpp* mutants and the *sax^P* mutant.

Example 5: Put, Tkv, Mad, Med, and Dad are Required Cell-Autonomously for Germline Stem Cell Maintenance.

To demonstrate definitively that *dpp* signaling was received by the germ line, studies were conducted to assess whether components of the signal transduction pathway are autonomously required in these cells. Flp-induced mitotic recombination was employed to generate marked clones homozygous for loss-of-function mutations in the germline stem cells of adult ovaries (see Experimental Procedures). Genes downstream of *dpp* in the signal transduction pathway are required in the germline stem cells for their division

and maintenance. Germaria lacking or bearing stem cell clones of the indicated genotypes were generated, and then labeled with anti-lacZ and anti-Hts antibodies. Marked stem cells and their progeny cysts were indicated by the absence of lacZ protein.

Clones were marked using *armadillo-lacZ*, which is strongly expressed in all cells within the germarium when wildtype flies are not subjected to heat shock. Stem cell clones can be recognized because only stem cells persist in the germarium more than 5 days after a mitotic recombination event (Margolis and Spradling, 1995). As recombination events can take place only in mitotically active adult cells, this method will not produce mutant clones in the terminally-differentiated terminal filament, cap cells, and inner sheath cells. Consequently, this approach excludes potential complications due to mutant clones in these surrounding somatic cells, allowing the autonomous function of genes to be tested in germline stem cells. This method has three major additional advantages. Firstly, the persistent mutant clones can be studied over a long period of time allowing germline stem cell maintenance to be quantified. Secondly, the existence of both a mutant and a wildtype stem cell side-by-side in the same germarium provides a control for the effects of gene removal by direct comparison. Thus, the relative division rates of these two stem cells can be determined simply by counting the number of mutant and wildtype cysts in germania with one mutant and one wildtype stem cell. Finally, germline stem cell-specific effects of the mutations can be assessed by looking at the developmental status of marked cystoblasts, cysts, and egg chambers.

Germline stem cell clones of *punt*-, *tkv*-, *mad*-, *Med*-, and *Dad*- were generated by subjecting females of the appropriate genotype to heat shock and examining their ovaries beginning one week later. Stem cells in the *Drosophila* ovary have a finite life span with a half-life of about 4.6 weeks (Margolis and Spradling, 1995; Table 2). In contrast to wildtype clones, stem cells mutant for each of the tested genes (except *Dad*) were lost more rapidly (Table 2). For example, after one week, the *punt*^{l35} mutant germline stem cell was either still present or had only recently been lost, as indicated by the presence of relatively young mutant cysts. However, after two weeks, the *punt*^{l35} mutant germline stem cell had usually been lost and only a few advanced mutant cysts remained.

mad^{l2} mutant stem cells were lost even more rapidly. After one week, the *mad*^{l2} mutant germline stem cell sometimes remained, but did not proliferate well as indicated by the lack of progeny cysts. More frequently, the germline stem cell was already lost and a more developed cyst (or cysts) was observed. After two weeks, *mad*^{l2} mutant germline

stem cells rarely remained so there were no mutant cysts, but older mutant egg chambers were present. Surprisingly, two wildtype germline stem cells were occasionally observed after the mutant stem cell was lost. These results indicate that the *dpp* signal directly acts on germline stem cells to regulate their maintenance. However, no effects were observed on the formation of 16-cell cysts or the subsequent development of germline cells.

Unlike the other tested genes, *Dad* is a negative regulator of *dpp* signaling. The *Dad* gene is induced by the *dpp* signaling pathway and antagonizes the function of *dpp* (Tsuneizumi et al., 1997). The *Dad*²⁷¹⁻⁶⁸ allele is a severe allele in which the entire C-terminal conserved domain was deleted (Tsuneizumi et al., 1997). Strikingly, germline stem cells mutant for *Dad*²⁷¹⁻⁶⁸ were not lost (e.g., a mutant germline stem cell and its progeny cysts may be present), even if both germline stem cells lacked this gene (e.g., two mutant germline stem cells and a normal complement of progeny cysts were present). No turnover could be detected even after three weeks of clone induction, suggesting that increasing *dpp* signaling can prolong germline stem cell lifetime.

To compare the magnitude of the effects of different mutations on stem cells, the half-life of mutant germline stem cells was measured (Table 2; Experimental Procedures). *punt*¹⁰⁴⁶⁰ is a hypomorphic allele of the Dpp type II receptor whereas *punt*¹³⁵ is a strong allele (Arora et al., 1995; Letsou et al., 1995). In *punt*¹⁰⁴⁶⁰ clones, germline stem cell half-life was reduced from about 4.6 to 0.90 weeks, whereas the stronger *punt*¹³⁵ allele reduced germline stem cell half-life to about 0.41 weeks. *tkv*⁸ is a strong allele of the type I receptor (Brummel et al., 1994; Nellen et al., 1994; Penton et al., 1994). *tkv*⁸ stem cell clones reduced germline stem cell half-life to about 0.69 weeks. Clones of two alleles of the downstream signal transducer, *mad*⁹ and *mad*¹², reduced germline stem cell half-life to 2.5 weeks and 0.25 weeks, respectively. Consistent with this observation, *mad*¹² is a much stronger allele than *mad*⁹ (Sekelsky et al., 1995). *Med*²⁶ is a strong allele of another downstream transducer (Des et al., 1998). *Med*²⁶ germline stem cells turned over with a half-life of about 0.38 weeks.

Example 6: Punt, Tkv, Mad, Med Are Required Cell-Autonomously to Stimulate Germline Stem Cell Division.

To further define the role of the *dpp* pathway in the regulation of germline stem cell division, the number of mutant and wildtype cysts in germaria carrying one mutant and one wildtype germline stem cell were compared. Since each cyst represents one germline stem cell division, counting the number of wildtype and mutant cysts allowed the

measure of relative germline stem cell division rates. All germaria that still retained a mutant germline stem cell from all three time points were counted and compared to the number of wildtype cysts. In controls containing a marked but genetically wildtype germline stem cell, approximately 50% of cysts were marked, indicating that two germline stem cells are present in one week-old adult germaria and divide at similar rates (see Table 2).

As expected based on previous experiments *punt*-, *tkv*-, *mad*-, and *Med*- mutant germline stem cells all divided more slowly than wildtype (see Table 2). While the relative division rate of marked wildtype germline stem cells was about 0.93, the rates in the tested genotypes ranged from about 0.21 to 0.60. These reductions mostly correlated with the known strength of these alleles, and with their effects on germline stem cell maintenance. However, both *punt*¹⁰⁴⁶⁰ and *punt*¹³⁵ mutant germline stem cells proliferated about three-fold slower than the wildtype, despite the fact that they differ in strength. Differences between the effects of these mutants on maintenance and division may reflect branch points in the pathway, and may suggest that at least one additional type II receptor also mediates germline stem cell behavior. Interestingly, *Dad*²⁷¹⁻⁶⁸ mutant germline stem cells, which were more stable than wildtype, divided at a similar or slightly slower rate than wildtype ones. These results demonstrate that components of the *dpp* signaling pathway are required autonomously for the proliferation of germline stem cells.

As shown previously, cysts produced in the presence of overexpressed *dpp* driven by *hs*-GAL4 always contained 16 cells. To verify that *dpp* signaling is not involved in regulating the cystoblast and cystocyte divisions, the number of germline cells in individual cysts mutant for *punt*¹⁰⁴⁶⁰, *mad*⁹, *mad*¹², *Med*²⁶, and *Dad*²⁷¹⁻⁶⁸ were counted. In every case, these cysts contained 16 cells, including a single oocyte. Therefore, the *dpp* signaling pathway specifically acts on stem cells within the germ line.

Example 7: *dpp* is Expressed in Differentiated Somatic Cells Surrounding Germline Stem Cells.

To directly localize the source of the Dpp signal, a whole mount mRNA *in situ* hybridization was performed to visualize expression of the *dpp* gene on two day-old wild-type females which were dissected and fixed. A standard protocol was used (Yue and Spradling, 1992) except that protease digestion was performed at 50 gm/ml for 5 min. No staining was observed using the *dpp* sense RNA probe as a control. Under the same conditions, the *dpp* anti-sense probe detected the *dpp* mRNA in the inner sheath cells and cap cells adjacent to germline stem cells, and in the posterior somatic follicle cells, but not in

germline and terminal filament cells. These expression data further support our finding that surrounding differentiated somatic cells constitute a niche for germline stem cells.

Example 8: A Lost Germline Stem Cell can be Replaced by the Daughter of the Other Stem Cell in the Same Germarium.

5 To provide further evidence that the stem cells in the ovariole reside within a niche, we showed that lost germline stem cells can be replaced and function as germline stem cells by cells that would otherwise differentiate. In one week-old germaria in which one stem cell is marked, the marked cell contributes almost 50% of cysts, suggesting there are an average of two germline stem cells per germarium. Since we have shown that wildtype
10 germline stem cells turn over with a half-life of 4.6 weeks, ovarioles containing only one or zero germline stem cells would arise at a predictable rate unless they are replaced. For example, after 4.6 weeks, 25%, 50% and 25% of the germaria are expected to have two, one, and zero germline stem cells. In contrast, we observed that more than 71% of five week-old germaria still contain two germline stem cells, 20% contained one germline stem
15 cell, and 9% contained none. These results were unexpected and demonstrate that following loss, germline stem cells are replaced 62% of the time over this time period.

To determine how replacement occurs, we identified ovarioles where a marked stem cell had just been lost and was in the process of being replaced. Such ovarioles contain a marked cystoblast and marked developing cysts, but no marked stem cell. We
20 observed an unusual division of the remaining stem cell in a plane perpendicular to the axis of the ovariole. Such a division would place the stem cell daughter in the same location as the recently lost stem cell. Normally, a germline stem cell divides along the anterior-posterior axis, and the posterior daughter differentiates into a cystoblast. These findings indicate that the fate of the stem cell daughter is determined by the environment.
25 This environment within the niche maintains the stem cell fate, while the environment more posteriorly in the ovariole promotes differentiation as a cystoblast.

Example 9: Dpp is Required for Maintenance of Male Germline Stem Cells.

Temperature sensitive *dpp* mutant genotypes were generated by crossing *dpp*^{hr56}/*CyO* with *dpp*^{hr4} and *dpp*^{e90}/*CyO*. Temperature-sensitive punt mutant males were generated by crossing *punt*¹⁰⁴⁶⁰/*TM3* with *punt*¹³⁵/*TM3* *Sb*. The *dpp*^{hr56}/*dpp*^{e90}, *dpp*^{hr56}/*dpp*^{hr4}
30 and *punt*¹⁰⁴⁶⁰/*punt*¹³⁵ adult males were raised at 28°C (i.e., the restrictive temperature) for one week. Heterozygotes controls were also examined at 28°C; testes were dissected out and stained with rabbit anti-Vasa and mouse anti-Hts antibodies. Cy3-conjugated goat

anti-rabbit and FITC-conjugated goat anti-mouse secondary antibodies were used to visualize the Vasa protein (red) and Hts protein (green) with a Leica TCS-NT confocal microscope. The germline stem cells are located at the tip of testes, and can be recognized by their expression of Vasa protein (red) and also contain round fusomes (yellow), and by their association with hub cells (green). The differentiated germline cells lie more distant from the tip, and also contain either round fusomes or branched fusomes.

To directly show that *dpp* regulates male germline stem cells in *Drosophila* testes, the number of stem cells was examined in *dpp^{hr56}/dpp^{e90}*, *dpp^{hr56}/dpp^{hr4}* and *punt¹⁰⁴⁶⁰/punt¹³⁵* mutant testes under restrictive conditions, and compared to heterozygote control testes. In a heterozygous testis (control), there were between seven and nine germline stem cells located adjacent to somatic hub cells and contain round fusomes like their counterparts in the ovary; these testes were full of developing germline cysts and primary spermatids. After one week at the restrictive temperature, there were still over seven germline stem cells. These values are indistinguishable from the typical wildtype testis. In contrast, one week-old *dpp^{hr56}/dpp^{e90}*, *dpp^{hr56}/dpp^{hr4}* and *punt¹⁰⁴⁶⁰/punt¹³⁵* mutant testes from males that had been raised at the restrictive temperature contained a reduced number of germline stem cells, ranging in number from 2-7 per testis. As a consequence of this loss, these testes were also significantly smaller than the controls and contained fewer developing germline cysts and primary spermatids. Because a testis starts with a much larger number of germline stem cells than an ovariole, complete loss would not be expected within one week even if they require *dpp* and *punt* to the same degree as female germline stem cells. These results demonstrate that *dpp* and *punt* are required for maintaining male germline stem cells.

Example 10: Shn is Required for Germline Stem Cell Maintenance.

schnurri (*shn*) encodes a zinc-finger protein homologous to human MPB1. It is required for *dpp* signaling in the *Drosophila* embryo (Arora et al., 1995; Greider et al., 1995). Mutant *shn* germline stem cell clones were generated as described above. FRT42D *arm-lacZ*/FRT42D *arm-lacZ* virgin females were crossed to FRT42D *shn*/CyO and FRT42D +/FRT42D + (control) males, respectively. Two day-old adult non-CyO females carrying an *arm-lacZ* transgene in trans to the *shn* mutant-bearing chromosomes were heat shocked twice at 37°C for 60 min each separated by eight hours. Germline stem cells were examined in the same manner as described above. These results demonstrate that *shn* is also required in germline stem cells for their maintenance and division.

EXPERIMENTAL PROCEDURES

A description of materials and methods useful for practicing the present invention is given in the following general references: Lindsley and Grell (*Genetic Variations of Drosophila melanogaster*, Carnegie Inst. of Wash., 1968); Ashburner (*Drosophila: A laboratory handbook and A laboratory manual*, Cold Spring Harbor Lab., 1989); Lindsley and Zimm (*The Genome of Drosophila melanogaster*, Academic, 1992); Bate and Arias (*The Development of Drosophila melanogaster*, Cold Spring Harbor Lab., 1993); and Greenspan (*Fly Pushing: The Theory and Practice of Drosophila Genetics*, Cold Spring Harbor Lab., 1997). *Drosophila* stocks may be obtained from the Bloomington Stock Center at Indiana University. Information relevant to *Drosophila* genetics and molecular biology, including recombinant clones and nucleotide/amino acid sequences obtained through the *Drosophila* genome project, is publicly available in the FLYBASE relational database (see Nucl. Acids Res. 27, 85-88, 1999).

Drosophila Stocks and Genetics

The following fly stocks used in this study were described either in the FlyBase or otherwise specified: *tkv*⁸; *punt*¹⁰⁴⁶⁰ and *punt*¹³⁵; *mad*⁹ and *mad*¹²; *Med*²⁶ (Des et al., 1998); *Dad*²⁷¹⁻⁶⁸; *sax*^P; *dpp*^{hr56} *dpp*^{hr4}, *dpp*^{e90}; UAS-*dpp*; *hs-GAL4*; HSF1p; FRT40A *armadillo-lacZ* and HSF1p; FRT82B *armadillo-lacZ* (Lecuit and Cohen, 1997); UAS-*tkv** (activated) and UAS-*sax** (activated) on both chromosomes 2 and 3 (Des et al., 1998). Most stocks were cultured at room temperature. To maximize their effects, *sax*^P and *dpp* mutants were cultured at 28°C for 1-2 weeks.

Generating Mutant Germline Stem Cell Clones and Overexpression

Clones of mutant cells were generated by Flp-mediated mitotic recombination as described previously (Xu and Rubin, 1993). To generate the stocks for stem cell clonal analysis, + FRT40A/CyO, *tkv*⁸ FRT40A/CyO, *mad*⁹ FRT40A/CyO, and *mad*¹² FRT40A/CyO males were mated with virgin females w HSF1p1; *armadillo-lacZ* FRT40A, respectively. FRT82B *Med*²⁶ /TM3 Sb, FRT82B *punt*¹³⁵ /TM3 Sb, FRT82B *punt*¹⁰⁴⁶⁰ /TM3 Sb, FRT82B *Dad*²⁷¹⁻⁶⁸ /TM3 Sb males were mated with virgin females w HSF1p1; FRT82B *armadillo-lacZ*, respectively. Two day-old adult non-CyO or non-Sb females carrying an *armadillo-lacZ* transgene in trans to the mutant-bearing chromosome were heat shocked at 37°C for 60 min. The females were transferred to fresh food every day at room temperature, and ovaries were removed one week, two weeks, or three weeks after the last heat shock-treatment and processed for antibody staining.

To construct the stocks for overexpressing *dpp* and activated receptors, the *hs-GAL4* virgins were crossed with *UAS-dpp*, *UAS-tkv*/CyO*, *UAS-tkv*/TM3 Sb*, *UAS-sax*/CyO*, *UAS-sax*/TM3 Sb*, *UAS-tkv*/CyO*; *UAS-sax*/TM6*, *UAS-sax*/CyO*; *UAS-tkv*/TM6* males, respectively. The females which did not carry balancer chromosomes were heat shocked at 37°C for 30 min each time with the interval of 12 hr for 3-5 days.

Calculations

To determine stem cell life spans, stem cells were marked in one to two day-old females of the appropriate genotype by a single heat pulse. Subsequently, ovaries were dissected from some of the females one, two, and three weeks later and stained with anti-Hts and anti-lacZ antibodies. The percentage of germaria containing a marked stem cell was determined by counts of 60-200 germaria at each time point, and used to calculate the stem cell half-life.

To measure stem cell division rates, we determined the relative number of wildtype and mutant cysts in germaria that contained one wildtype and one mutant stem cell. A relative division rate of 1.0 would indicate normal division. For a given genotype, these values were similar at each time point, and the average is presented in Table 2. Marked wildtype stem cells gave a value of 0.93 rather than 1.0 probably due to a small fraction of germaria that contained three rather than two germline stem cells.

To measure stem cell loss, germaria with two, one, or no germline stem cells, were counted from the ovaries of the one and two week-old females. Heterozygous females carrying one copy of the mutant gene in combination with a *CyO* balancer chromosome containing a *dpp* transgene (Hursh et al., 1993) served as a control. Values are expressed as the percentage of ovarioles with the indicated stem cell compositions.

Immunohistochemistry

The following antisera at the indicated dilutions were used: polyclonal anti-Vasa antibody (1:2000) (Liang et al., 1990); monoclonal anti-Hts antibody 1B1 (1:5) (Zacci and Lipshitz, 1996); polyclonal anti- α -spectrin antibody (1:100) (Byers et al., 1987); rat anti-Bam antibody (1:100) (McKearin and Ohlstein, 1995); monoclonal anti-BrdU antibody (1:50) (Becton-Dickinson); polyclonal anti- β -galactosidase antibody (1:1000) (Cappel). Labeling with BrdU was carried out for 1 hour at room temperature as described by de Cuevas and Spradling (1998). All photomicrographs were taken using a Leica TCS-NT confocal microscope.

Table 1. Dpp is Required for Germline Stem Cell Maintenance.

	Genotypes	<u>One week</u>			<u>Two weeks</u>		
		No	One	Two	No	One	Two
		GSC	GSC	GSC	GSC	GSC	GSC
5	<i>dpp^{e90}/CyOP23</i>	0.0%	4.4%	95.6%	0.5%	17.5%	82.0%
		(0)	(5)	(108)	(1)	(36)	(168)
	<i>dpp^{hr4}/CyOP23</i>	0.0%	3.5%	96.5%	1.5%	23.9%	74.6%
		(0)	(6)	(165)	(3)	(48)	(150)
	<i>dpp^{e90}/dpp^{hr56}</i>	16.0%	29.3%	54.7%	47.3%	39.8%	12.9%
10		(17)	(31)	(58)	(140)	(118)	(38)
	<i>dpp^{hr4}/dpp^{hr56}</i>	18.1%	33.9%	48.0%	98.4%	1.6%	0.0%
		(22)	(41)	(58)	(122)	(2)	(0)

15 The percentage of ovarioles with zero, one or two germline stem cells is given for each genotype. Actual numbers are given in parentheses.

^aP23 is a *dpp* transgene on the CyO chromosome (Hursh et al., 1993).

Table 2. Downstream Components of the *dpp* Pathway are Required in Germline Stem Cells for their Maintenance and Division.

		Percent of Germaria ^a			GSC ^b	Relative ^c
		with a Marked GSC				
5	Strains	1 week	2 weeks	3 weeks	Half-Life (weeks)	Division Rate
10	Control	37.7 (138)	34.4 (161)	27.5 (160)	4.6	0.93 (1410)
	<i>punt</i> ¹⁰⁴⁶⁰	43.2 (118)	26.4 (182)	9.5 (116)	0.90	0.36 (1126)
	<i>punt</i> ¹³⁵	27.4 (95)	5.1 (138)	0 (114)	0.41	0.37 (329)
	<i>tkv</i> ⁸	38.6 (132)	16.4 (176)	6.1 (197)	0.69	0.29 (744)
	<i>mad</i> ⁹	43.6 (g4)	29.3 (208)	25.8 (155)	2.5	0.60 (1116)
	<i>mad</i> ¹²	17.8 (124)	0(108)	0.7 (136)	0.25	0.21 (214)
	<i>Med</i> ²⁶	23.8 (172)	7.3 (110)	0 (122)	0.38	0.39 (512)
15	<i>Dad</i> ²⁷¹⁻⁶⁸	28.0 (107)	32.6 (86)	32.3 (62)	>>4.6	0.84 (770)
	Control	41.3 (235)	33.8 (185)	32.1 (379)	4.7	1.16 (316)
	<i>shnP</i>	38.9 (126)	23.7 (228)	16.5 (332)	2.2	0.53 (331)

^aNumber of germaria with lacZ-negative germline stem cell clone / total germaria X 100.

20 The actual number of germaria counted is given in parentheses.

^bCalculated as described in Experimental Procedures.

^cCalculated as described in Experimental Procedures. The number of cysts counted is given in parentheses.

25 While the present invention has been described by what is presently considered to be practical and preferred embodiments, it is to be understood that variations in the claimed invention will be obvious to skilled artisans without departing from the novel aspects of the present invention and that such variations are intended to come within the scope of the claims.

30 For example, components of the *dpp* signaling pathway are conserved in structure (e.g., amino acid residues are identical or chemically analogous in a high proportion of positions when sequences are aligned) and function such that mammalian proteins can rescue Drosophila mutant phenotypes which result from mutations in homologous gene of the pathway. Equivalents to the Drosophila genes and proteins identified herein, as well as

mutants thereof, would be known to skilled artisans practicing the present invention by their similarity in amino acid sequence (e.g., members of the TGF- β family) and/or their ability to at least partially rescue mutant phenotypes or to create phenocopies of such phenotypes.

5 Thus, the extent of legal protection will be determined by the limitations recited in the allowed claims and their equivalents. Unless explicitly recited, other aspects of the present invention as described in this specification do not limit the scope of the claims. In this regard, the mechanisms of action suggested in the specification (e.g., models for BMP signaling) are merely possible explanations for our observations while operation of the
10 claimed invention is not necessarily dependent thereon.

 All references, patent applications, and patents cited in this disclosure are hereby incorporated herein by reference in their entirety and indicate the high skill of artisans in this field. In particular, some of the results shown above were published by Xie and Spradling in Cell 94, 251-260 (1998) after the filing date of priority U.S. Appl. No.
15 60/094,008.

REFERENCES

- Allis et al. (1979) Develop. Biol. 69, 451-65.
Arora et al. (1995) Cell 81, 781-790.
20 Attisano and Wrana (1998) Curr. Opin. Cell Biol. 10, 188-194.
Baker et al. (1992) Genes Develop. 6, 2312-2326.
Beyers et al. (1987) J. Cell Biol. 105, 2103-2110.
Bitgood and McMahon (1995) Develop. Biol. 172, 126-138.
Brand and Perrimon (1993) Development 118, 401-415.
25 Brook and Cohen (1996) Science 273, 1373-1377.
Brummel et al. (1994) Cell 78, 251-261.
Burke and Basler (1996) Development 122, 2261-2269.
Burke et al. (1984) Somat. Cell. Mol. Genet. 10, 579-588.
Cadigan and Nusse (1997) Genes Develop. 11, 3286-3305.
30 Campbell and Tomlinson (1999) Cell 96, 553-562.
Capecchi (1989) Science 244, 1288-1292.
Chen and Baker (1996) Development 124, 205-218.
Das et al. (1998) Development 125, 1519-1528.

- de Cuevas et al. (1997) *Annu. Rev. Genet.* 31, 405-428.
- de Cuevas and Spradling (1998) *Development* 125, 2781-2789.
- Doe and Spana (1995) *Neuron* 15, 991-995.
- Forbes et al. (1996a) *Development* 122, 1125-1135.
- 5 Forbes et al. (1996b) *Development* 122, 3283-3294.
- Forbes and Lehmann (1998) *Development* 125, 679-690.
- Gateff and Mechler (1989) *Crit. Rev. Oncogen.* 1, 221-245.
- Greider et al. (1995) *Cell* 81, 791-800.
- Groppe et al. (1998) *J. Biol. Chem.* 273, 29052-29065.
- 10 Haerry et al. (1998) *Development* 125, 3977-3987.
- Heldin et al. (1997) *Nature* 390, 465-471.
- Hoffman (1992) *Mol. Reprod. Develop.* 32, 173-178.
- Hogan (1996a) *Genes Develop.* 10, 1580-1594.
- Hogan (1996b) *Curr. Opin. Genet. Develop.* 6, 432-438.
- 15 Hudson et al. (1998) *Development* 125, 1407-1420.
- Hursh et al. (1993) *Development* 117, 1211-1222.
- Inoue et al. (1998) *Mol. Biol. Cell* 9, 2145-2156.
- Jazwinska et al. (1999) *Cell* 96, 563-573.
- Jiang and Struhl (1996) *Cell* 86, 401-409.
- 20 Johnson and Tabin (1995) *Cell* 81, 313-316.
- Kawabata et al. (1998) *Cytokine Growth Factor Rev.* 9, 49-61.
- Koller and Smithies (1992) *Annu. Rev. Immunol.* 10, 705-730.
- Lagna et al. (1996) *Nature* 383, 832-836.
- Lawrence and Struhl (1996) *Cell* 85, 951-961.
- 25 Lawson et al. (1999) *Genes Develop.* 13, 424-436.
- Lecuit and Cohen (1997) *Nature* 388, 139-145.
- Lee et al. (1994) *Science* 266, 1528-1537.
- Lengyel et al. (1975) *Meth. Cell Biol.* 10, 195-208.
- Letsou et al. (1995) *Cell* 80, 899-908.
- 30 Liang et al. (1994) *Development* 120, 1201-1211.
- Lin (1997) *Annu. Rev. Genet.* 31, 455-491.
- Lin et al. (1994) *Development* 120, 947-956.
- Lin and Spradling (1997) *Development* 124, 2463-2476.

- Manseau et al. (1997). *Develop. Dynamics* 209, 310-322.
- Margolis and Spradling (1995) *Development* 121, 3797-3807.
- Massague (1996) *Cell* 85, 947-950.
- Matunis et al. (1997). *Development* 124, 4383-4391.
- 5 McKearin and Ohlstein (1995) *Development* 121, 2937-2947.
- McKearin and Spradling (1990) *Genes Develop.* 4, 2242-2251.
- Minami et al. (1999) *Nature* 398, 242-246.
- Mishina et al. (1995) *Genes Develop.* 9, 3027-3037.
- Morrison et al. (1997) *Cell* 88, 287-298.
- 10 Murata and Wharton (1995) *Cell* 80, 747-756.
- Nellen et al. (1994) *Cell* 78, 225-237.
- Nellen et al. (1996) *Cell* 85, 357-368.
- Newfeld et al. (1997) *Genetics* 145, 297-309.
- Ohlstein and McKearin (1997) *Development* 124, 3651-3662.
- 15 Okada et al. (1974) *Develop. Biol.* 39, 286-294.
- Padgett (1999) *Curr. Biol.* 9, R408-411.
- Padgett et al. (1987) *Nature* 325, 81-84.
- Padgett et al. (1993) *Proc. Natl. Acad. Sci. USA* 90, 2905-2909.
- Padgett et al. (1998) *Bioessays* 20, 382-390.
- 20 Panganiban et al. (1990) *Mol. Cell. Biol.* 10, 2669-2277.
- Penton et al. (1994) *Cell* 78, 239-250.
- Penton et al. (1997) *Science* 275, 203-206.
- Perrimon (1995) *Cell* 80, 517-520.
- Potter and Loeffler (1990) *Development* 110, 1001-1020.
- 25 Raftery and Sutherland (1999) *Develop. Biol.* 210, 251-268.
- Ruberte et al. (1995) *Cell* 80, 889-897.
- Schneider (1972) *J. Embryol. Exp. Morphol.* 27, 353-365.
- Schoffeld, R. (1978) *Blood Cells* 4, 7-25.
- Sekelsky et al. (1995) *Genetics* 139, 1347-1358.
- 30 Spradling et al. (1975) *Meth. Cell Biol.* 10, 185-194.
- Spradling et al. (1995) *Proc. Natl. Acad. Sci. USA* 92, 10824-10830.
- Spradling et al. (1997) *Cold Spring Harbor Symp. Quant. Biol.* 62, 25-34.
- Tsuneizumi et al. (1997) *Nature* 389, 627-631.

- Twombly et al. (1996) *Development* 122, 1555-1565.
- Van Deusen (1977) *J. Embryol. Exp. Morphol.* 37, 173-185.
- Wharton et al. (1996) *Genetics* 142, 493-505.
- Wharton et al. (1999) *Genetics* 152, 629-640.
- 5 Wieschaus and Szabad (1979) *Develop. Biol.* 68, 29-46.
- Winnier et al. (1995) *Genes Develop.* 9, 2105-2116.
- Wisotzkey et al. (1998) *Development* 125, 1433-1445.
- Xie et al. (1994) *Science* 263, 1756-1759.
- Xu and Rubin (1993) *Development* 117, 1223-1237.
- 10 Yamaji et al. (1994) *Biochem. Biophys. Res. Commun.* 205, 1944-1951.
- Zacci and Lipshitz (1996) *Zygote* 4, 159-166.
- Zhang and Spradling (1994) *Proc. Natl. Acad. Sci. USA* 91, 3539-3543.
- Zhang and Bradley (1996) *Development* 122, 2977-2986.
- Zhao et al. (1996) *Genes Develop.* 10, 1657-1669.
- 15 Zhao et al. (1998) *Development* 125, 1103-1112.

Standard procedures in the art are described in generally available references and laboratory manuals like Ausubel et al. (*Current Protocols in Molecular Biology*, Wiley, 1999); Birren et al. (*Genome Analysis Series*, CSHL, 1997-1999); Coligan et al. (*Current*

20 *Protocols in Immunology*, Wiley, 1999); Coligan et al. (*Current Protocols in Protein Science*, Wiley, 1999); Diffenbach and Dveksler (*PCR Primer*, CSHL Press, 1995); Harlow and Lane (*Antibodies and Using Antibodies*, CSHL, 1988 and 1999); Hogan et al. (*Manipulating the Mouse Embryo*, CSHL, 1994); Janson and Ryder (*Protein Purification*, Wiley, 1997); Keller and Manak (*DNA Probes*, Stockton, 1993); Marshak et al. (*Strategies*

25 *for Protein Purification and Characterization*, CSHL, 1996); Mullis et al. (*The Polymerase Chain Reaction*, Birkhauser, 1994); Murphy and Carter (*Transgenesis Techniques*, Humana, 1993); Pinkert, (*Transgenic Animal Technology*, Academic, 1994); Sambrook et al. (*Molecular Cloning*, CSHL, 1989); and Spector et al. (*Cells*, CSHL, 1998).

WE CLAIM:

1. A method for maintaining germline stem cells of *Drosophila* comprising:
 - (a) providing a population comprised of said germline stem cells, and
 - (b) stimulating signal transduction by a bone morphogenetic protein (BMP) signaling pathway in at least one cell of said population; wherein said stimulation maintains more germline stem cells in said population as compared to a population which has not had signal transduction of said BMP signaling pathway stimulated.
2. A method according to Claim 1, wherein said population is maintained *in vivo* and said *Drosophila* has been genetically engineered to stimulate said signal transduction.
3. A method according to Claim 1, wherein said population is maintained *in vitro*.
4. A method according to Claim 1, wherein said germline stem cells are from ovary.
5. A method according to Claim 1, wherein said germline stem cells are from testis.
6. A method according to Claim 1 further comprising obtaining said germline stem cells from an embryo.
7. A method according to Claim 1, wherein said BMP signaling pathway is stimulated by providing at least 10% more Decapentaplegic (Dpp) activity to said population than is present in wildtype.
8. A method according to Claim 1, wherein said BMP signaling pathway is stimulated by at least mutating a *dpp* gene to a gain-of-function phenotype.
9. A method according to Claim 1, wherein said BMP signaling pathway is stimulated by at least providing a BMP to said population.
10. A method according to Claim 9, wherein said BMP is selected from the group consisting of Decapentaplegic (Dpp) protein, BMP-2, and BMP-4.

11. A method according to Claim 1, wherein said BMP signaling pathway is stimulated by at least mutating a type I or type II decapentaplegic (*dpp*) receptor to a gain-of-function phenotype.
12. A method according to Claim 1, wherein said BMP signaling pathway is stimulated through at least one serine/threonine kinase receptor which specifically recognizes a BMP.
13. A method according to Claim 12, wherein said BMP receptor is selected from the group consisting of Saxophone (Sax), Thick veins (Tkv), and Punt (Put).
14. A method according to Claim 1, wherein said BMP signaling pathway is stimulated by altering activity of at least one signal transducer for receptor binding to a BMP.
15. A method according to Claim 14, wherein said signal transducer is selected from the group consisting of Mothers against *dpp* (Mad), Medea (Med), Daughters against *dpp* (Dad), Schnurri (Shn), and Brinker (Brk).
16. A method according to Claim 1, wherein said BMP signaling pathway is stimulated by increasing expression of BMP in a cell of said population.
17. A method according to Claim 16, wherein BMP expression is increased by *hedgehog* (*hh*)-activated transcription or *wingless* (*wg*)-activated transcription, and BMP signaling is increased in at least some of the germline stem cells.
18. A method according to Claim 1, wherein said population is further comprised of at least one somatic cell selected from the group consisting of terminal filament cell, cap cell, inner sheath cell, hub cell, and cyst progenitor cell.
19. A method according to Claim 1, wherein at least one germline stem cell is cultured *in vitro* in contact with feeder cells expressing a bone morphogenetic protein (BMP).

20. A method according to Claim 1, wherein at least one germline stem cell is cultured *in vitro* in contact with at least some somatic niche cells.

21. A method according to Claim 1, wherein signal transduction through said BMP signaling pathway is stimulated by *in vitro* culturing said germline stem cells with a feeder layer of somatic cells which stimulate BMP signaling.

22. A method according to Claim 1, wherein signal transduction through said BMP signaling pathway is stimulated by *in vitro* culturing said germline stem cells in a culture medium which stimulates BMP signaling.

23. A method according to Claim 1 further comprising maintaining at least one of said germline stem cells in a pluripotent state.

24. A method according to Claim 1 further comprising maintaining at least one of said germline stem cells in a totipotent state.

25. A method according to Claim 1 further comprising transferring at least one of said stimulated germline stem cells into a host *Drosophila*.

26. A method according to Claim 25, wherein at least one of said transferred germline stem cells contributes to two or more differentiated cell lineages of said host *Drosophila*.

27. A method according to Claim 25, wherein at least one of said transferred germline stem cells contributes to a germline cell lineage of said host *Drosophila*.

28. A method according to Claim 1 further comprising mutating at least one gene of said germline stem cell's genome.

29. A method according to Claim 1 further comprising introducing one or more polynucleotides into said germline stem cell's genome.

30. A method according to Claim 1 further comprising integrating a polynucleotide by homologous recombination at a targeted genetic locus of said germline stem cell.

31. A method according to Claim 1 further comprising targeting at least one gene of said germline stem cell for homologous recombination, selecting at least one germline stem cell which has undergone homologous recombination of said gene, and transferring said homologously recombined germline stem cells into another *Drosophila* such that said targeted gene is genetically transmitted through said another *Drosophila*'s germline.

32. A cell population made by a method according to Claim 1, wherein there are at least ten germline stem cells in said population for each germline stem cell present prior to stimulation of BMP signaling.

33. A method for maintaining *Drosophila* stem cells comprising:
(a) providing a population comprised of said stem cells, and
(b) stimulating *decapentaplegic* (*dpp*) signaling such that more stem cells of said population are maintained as at least viable or undifferentiated as compared to a population of stem cells which has not been stimulated.

34. A method of reducing or eliminating stem cells or tumor cells of an organism comprising: repressing signal transduction by a bone morphogenetic protein (BMP) receptor pathway such that said stem cells or tumor cells are reduced or eliminated.

35. A method of increasing abundance of stem cells of an organism comprising: stimulating signal transduction by a bone morphogenetic protein (BMP) receptor pathway such that abundance of at least some stem cells is increased.

36. A method of increasing lifetime of stem cells of an organism comprising: stimulating signal transduction by a bone morphogenetic protein (BMP) receptor pathway such that said lifetime of at least some stem cells is increased.

ABSTRACT OF THE DISCLOSURE

The TGF- β family of growth factors, particularly the bone morphogenetic protein (BMP)-2/4 homolog decapentaplegic (*dpp*), are specifically required to maintain germline
5 stem cells and promote their division. Overexpression of *dpp* blocks germline stem cell differentiation. Mutations in *dpp* or its receptor *saxophone* accelerate stem cell loss and retard stem cell division. *dpp* signaling is directly received by germline stem cells, and thus *dpp* signaling helps define a niche that controls germline stem cell proliferation.